Research programme: immunoglobulins - Trillium Therapeutics

Drug Profile

Research programme: immunoglobulins - Trillium Therapeutics

Latest Information Update: 04 Jun 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Hospital for Sick Children; University Health Network
  • Developer The Hospital for Sick Children; Trillium Therapeutics Inc; University Health Network
  • Class Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action SIRPA protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 17 Jan 2018 Trillium plans a phase Ia/Ib trial for Lymphoma or Multiple myeloma (Combination therapy, Second line therapy or greater) in Canada in second half of 2018
  • 17 Jan 2018 Trillium announces intention to submit IND for TTI 622 to the US-FDA for Cancer in second half of 2017
  • 02 Jun 2014 Stem Therapeutics changes its name to Trillium Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top